Secreted CLU is associated with the initiation of triple-negative breast cancer

Cancer Biology and Therapy

Volumn 13, Issue 5, 2012, Pages 321-329

  Zhang, Danfang ^a   Sun, Baocun ^a   Zhao, Xiulan ^a   Cui, Yanfen ^a   Xu, Shaoyan ^a   Dong, Xueyi ^a   Zhao, Jianmin ^a   Meng, Jie ^a   Jia, Xiaohua ^a   Chi, Jiadong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Human triple negative breast cancer; Secreted clusterin; Spontaneous breast cancer; Ta2 mouse

Indexed keywords

CLUSTERIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; AXILLARY LYMPH NODE; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CLINICAL FEATURE; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAMMARY GLAND; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING;

EID: 84863282071     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.19072     Document Type: Article

References (37)

1. von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neoadjuvant chemotherapy trials. Breast Cancer Res Treat 2011; 125:145-56; PMID:21042932; http://dx.doi. org/10.1007/s10549-010-1228-x.
2. Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MCU, Akslen LA, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007; 7:134; PMID:17650314; http://dx.doi.org/10.1186/1471-2407-7-134.
3. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)- negative, progesterone receptor (PR)-negative and HER2-negative invasive breast cancer, the so-called triple- negative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109:1721-8; PMID:17387718; http://dx.doi.org/10.1002/cncr.22618.
4. Takei H, Kurosumi M, Yoshida T, Hayashi Y, Higuchi T, Uchida S, et al. Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages? Breast Cancer 2011; 18:85-91; PMID:21104350; http://dx.doi.org/10.1007/s12282-010-0239-0.
5. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58:2825-31; PMID:9661897.
6. Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 2011; 125:627-36; PMID:21161370; http://dx.doi.org/10.1007/s10549-010-1293-1.
7. Lund MJB, Butler EN, Bumpers HL, Okoli J, Rizzo M, Hatchett N, et al. High prevalence of triplenegative tumors in an urban cancer center. Cancer 2008; 113:608-15; PMID:18484596; http://dx.doi. org/10.1002/cncr.23569.
8. Yuan ZY, Wang SS, Gao Y, Su ZY, Luo WB, Guan Z-Z. Clinical characteristics and prognosis of triple-negative breast cancer: a report of 305 cases. Ai Zheng 2008; 27:561-5; PMID:18570725.
9. Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, Liu GY, et al. Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat 2009; 115:325-33; PMID:18563552; http:// dx.doi.org/10.1007/s10549-008-0096-0.
10. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363:1938-48; PMID:21067385; http://dx.doi.org/10.1056/ NEJMra1001389.
11. De Laurentiis M, Cianniello D, Caputo R, Stanzione B, Arpino G, Cinieri S, et al. Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev 2010; 36:80-6; PMID:21129616; http://dx.doi.org/10.1016/S0305-7372(10)70025-6.
12. Santana-Davila R, Perez EA. Treatment options for patients with triple-negative breast cancer. J Hematol Oncol 2010; 3:42; PMID:20979652; http://dx.doi. org/10.1186/1756-8722-3-42.
13. Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995; 27:633-45; PMID:7648419; http://dx.doi.org/10.1016/1357-2725(95)00027-M.
14. Sallman DA, Chen X, Zhong B, Gilvary DL, Zhou J, Wei S, et al. Clusterin mediates TRAIL resistance in prostate tumor cells. Mol Cancer Ther 2007; 6:2938-47; PMID:18025278; http://dx.doi. org/10.1158/1535-7163.MCT-07-0345.
15. 2+ depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. Cell Death Differ 2005; 12:101-4; PMID:15499376; http://dx.doi.org/10.1038/sj.cdd.4401491.
16. Lakins JN, Poon S, Easterbrook-Smith SB, Carver JA, Tenniswood MPR, Wilson MR. Evidence that clusterin has discrete chaperone and ligand binding sites. Biochemistry 2002; 41:282-91; PMID:11772027; http://dx.doi.org/10.1021/ bi0157666.
17. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 2001; 3:360-7; PMID:11571636; http://dx.doi.org/10.1038/sj.neo.7900174.
18. Hara I, Miyake H, Gleave ME, Kamidono S. Introduction of clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo. Jpn J Cancer Res 2001; 92:1220-4; PMID:11714447; http://dx.doi.org/10.1111/j.1349- 7006.2001.tb02143.x.
19. Rizzi F, Bettuzzi S. Targeting Clusterin in prostate cancer. J Physiol Pharmacol 2008; 59:265-74; PMID:19261985.
20. Zhang S, Zhang D, Zhu Y, Guo H, Zhao X, Sun B. Clusterin expression and univariate analysis of overall survival in human breast cancer. Technol Cancer Res Treat 2006; 5:573-8; PMID:17121433.
21. Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W, et al. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ 2006; 13:12-9; PMID:16179938; http://dx.doi.org/10.1038/sj.cdd.4401779.
22. Redondo M, Villar E, Torres-Muñoz J, Tellez T, Morell M, Petito CK. Overexpression of clusterin in human breast carcinoma. Am J Pathol 2000; 157:393-9; PMID:10934144; http://dx.doi.org/10.1016/S0002-9440(10)64552-X.
23. Krüger S, Ola V, Fischer D, Feller AC, Friedrich M. Prognostic significance of clusterin immunoreactivity in breast cancer. Neoplasma 2007; 54:46-50; PMID:17203891.
24. Flanagan L, Whyte L, Chatterjee N, Tenniswood M. Effects of clusterin overexpression on metastatic progression and therapy in breast cancer. BMC Cancer 2010; 10:107; PMID:20307318; http://dx.doi.org/10.1186/1471-2407-10-107.
25. Sutton D, Kim S, Shuai X, Leskov K, Marques JT, Williams BRG, et al. Efficient suppression of secretory clusterin levels by polymer-siRNA nanocomplexes enhances ionizing radiation lethality in human MCF-7 breast cancer cells in vitro. Int J Nanomedicine 2006; 1:155-62; PMID:17722531; http://dx.doi.org/10.2147/nano.2006.1.2.155.
26. Sun B, Zhang S, Zhang D, Li Y, Zhao X, Luo Y, et al. Identification of metastasis-related proteins and their clinical relevance to triple-negative human breast cancer. Clin Cancer Res 2008; 14:7050-9; PMID:18981002; http://dx.doi.org/10.1158/1078-0432.CCR-08-0520.
27. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121; PMID:21633166; http://dx.doi. org/10.1172/JCI45014.
28. Rizzi F, Bettuzzi S. The clusterin paradigm in prostate and breast carcinogenesis. Endocr Relat Cancer 2010; 17:1-17; PMID:19903745; http://dx.doi.org/10.1677/ ERC-09-0140.
29. Cappelletti V, Gariboldi M, De Cecco L, Toffanin S, Reid JF, Lusa L, et al. Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. Endocr Relat Cancer 2008; 15:439-49; PMID:18508997; http://dx.doi.org/10.1677/ERC-07-0274.
30. Trougakos IP, Lourda M, Antonelou MH, Kletsas D, Gorgoulis VG, Papassideri IS, et al. Intracellular clusterin inhibits mitochondrial apoptosis by suppressing p53-activating stress signals and stabilizing the cytosolic Ku70-Bax protein complex. Clin Cancer Res 2009; 15:48-59; PMID:19118032; http://dx.doi. org/10.1158/1078-0432.CCR-08-1805.
31. Niu L, Zang J, Cai L, Li C, Cao H. Relationship of clusterin expression with Bax and p53 expression in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2007; 10:284-7; PMID:21122294.
32. So A, Sinnemann S, Huntsman D, Fazli L, Gleave M. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol Cancer Ther 2005; 4:1837-49; PMID:16373699; http://dx.doi.org/10.1158/1535-7163.MCT-05-0178.
33. Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:4247-54; PMID:20733135; http:// dx.doi.org/10.1200/JCO.2009.26.8771.
34. Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005; 97:1287-96; PMID:16145049; http://dx.doi.org/10.1093/jnci/dji252.
35. Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, et al. A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin Cancer Res 2008; 14:833-9; PMID:18245546; http://dx.doi.org/10.1158/1078-0432. CCR-07-1310.
36. Chia S, Dent S, Ellard S, Ellis PM, Vandenberg T, Gelmon K, et al. Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin Cancer Res 2009; 15:708-13; PMID:19147778; http://dx.doi.org/10.1158/1078- 0432.CCR-08-1159.
37. Zoubeidi A, Chi K, Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 2010; 16:1088-93; PMID:20145158; http://dx.doi.org/10.1158/1078-0432.CCR-09-2917.